Amylyx Pharmaceuticals, Inc.
AMLX
$14.44
-$0.44-2.96%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -150.11M | -144.74M | -149.28M | -187.60M | -218.86M |
| Total Depreciation and Amortization | 467.00K | 525.00K | 577.00K | 678.00K | 745.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 26.38M | 21.95M | 22.14M | 57.81M | 66.33M |
| Change in Net Operating Assets | 2.86M | -1.08M | -27.88M | -36.54M | -55.20M |
| Cash from Operations | -120.40M | -123.34M | -154.45M | -165.65M | -206.98M |
| Capital Expenditure | -127.00K | -138.00K | -36.28M | -36.23M | -36.30M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 94.09M | 14.18M | 85.83M | 119.36M | 67.48M |
| Cash from Investing | 93.96M | 14.04M | 49.55M | 83.13M | 31.18M |
| Total Debt Issued | 190.74M | 256.31M | 256.69M | 65.58M | 65.58M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 10.27M | 4.08M | 3.85M | 1.68M | 1.66M |
| Repurchase of Common Stock | -6.42M | -3.36M | -3.19M | -1.44M | -1.35M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 194.58M | 257.03M | 257.35M | 65.82M | 65.88M |
| Foreign Exchange rate Adjustments | 766.00K | 1.07M | 431.00K | 516.00K | -131.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 168.91M | 148.80M | 152.88M | -16.18M | -110.06M |